Published in Eur Heart J on August 01, 2000
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov (2007) 2.32
Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol (2004) 2.05
Genetics of acquired long QT syndrome. J Clin Invest (2005) 1.96
A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. Circ Cardiovasc Genet (2011) 1.48
Mechanism of action of a novel human ether-a-go-go-related gene channel activator. Mol Pharmacol (2005) 1.43
Clinical cardiac safety profile of nilotinib. Haematologica (2012) 1.13
Genome wide analysis of drug-induced torsades de pointes: lack of common variants with large effect sizes. PLoS One (2013) 1.04
Cellular basis of drug-induced torsades de pointes. Br J Pharmacol (2008) 1.02
No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a 'thorough QT/QTc study' performed according to ICH guidelines. Br J Clin Pharmacol (2010) 1.02
Cardiac safety, drug-induced QT prolongation and torsade de pointes (TdP). Br J Clin Pharmacol (2012) 1.01
More light on QT interval measurement. Heart (2002) 1.00
Drug-induced arrhythmia: pharmacogenomic prescribing? Eur Heart J (2012) 1.00
Fever accentuates transmural dispersion of repolarization and facilitates development of early afterdepolarizations and torsade de pointes under long-QT Conditions. Circ Arrhythm Electrophysiol (2008) 0.99
Phase 2 ventricular arrhythmias in acute myocardial infarction: a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology evaluation. Br J Pharmacol (2005) 0.99
QTc Interval and QT Dispersion in Patients with Thalassemia Major: Electrocardiographic (EKG) and Echocardiographic Evaluation. Clin Med Insights Cardiol (2010) 0.92
Methodological considerations in the design of trials for safety assessment of new drugs and chemical entities. Curr Control Trials Cardiovasc Med (2005) 0.87
The organic cation transporter, OCTN1, expressed in the human heart, potentiates antagonism of the HERG potassium channel. J Cardiovasc Pharmacol (2009) 0.86
In silico analysis of conformational changes induced by mutation of aromatic binding residues: consequences for drug binding in the hERG K+ channel. PLoS One (2011) 0.85
Accuracy of popular automatic QT interval algorithms assessed by a 'gold standard' and comparison with a Novel method: computer simulation study. BMC Cardiovasc Disord (2005) 0.84
Novel genes for QTc interval. How much heritability is explained, and how much is left to find? Genome Med (2010) 0.84
Drug-like property profiling of novel neuroprotective compounds to treat acute ischemic stroke: guidelines to develop pleiotropic molecules. Transl Stroke Res (2013) 0.81
Long QT interval in Turner syndrome--a high prevalence of LQTS gene mutations. PLoS One (2013) 0.81
Genetic determinants of response to cardiovascular drugs. Curr Opin Cardiol (2012) 0.80
Influence of the G2677T/C3435T haplotype of MDR1 on P-glycoprotein trafficking and ibutilide-induced block of HERG. Pharmacogenomics J (2009) 0.80
The acquired Brugada syndrome and the paradox of choice. Heart Rhythm (2009) 0.79
Replacing the thorough QT study: reflections of a baby in the bath water. Br J Clin Pharmacol (2014) 0.79
Clarithromycin-Induced Long QT Syndrome: A Case Report. Case Rep Med (2012) 0.78
Comparison of electrophysiological effects of calcium channel blockers on cardiac repolarization. Korean J Physiol Pharmacol (2015) 0.77
Pronounced effects of HERG-blockers E-4031 and erythromycin on APD, spatial APD dispersion and triangulation in transgenic long-QT type 1 rabbits. PLoS One (2014) 0.77
Pharmacokinetic-pharmacodynamic modelling of drug-induced QTc interval prolongation in man: prediction from in vitro human ether-à-go-go-related gene binding and functional inhibition assays and conscious dog studies. Br J Pharmacol (2016) 0.77
Cardiologic side effects of psychotropic drugs. J Geriatr Cardiol (2011) 0.76
Evaluation of QT Interval in β Thalassemia Major Patients in Comparison with Control Group. Heart Views (2012) 0.75
Effects of As2O3 nanoparticles on cell growth and apoptosis of NB4 cells. Exp Ther Med (2015) 0.75
Assessment of proarrhythmic activity of chloroquine in in vivo and ex vivo rabbit models. J Pharmacol Pharmacother (2013) 0.75
Comparative cardiovascular safety of risperidone and olanzapine, based on electrocardiographic parameters and blood pressure: a prospective open label observational study. Indian J Pharmacol (2014) 0.75
The influence of type 2 diabetes and gender on ventricular repolarization dispersion in patients with sub-clinic left ventricular diastolic dysfunction. Am J Cardiovasc Dis (2015) 0.75
Analysis of West Virginia medicaid claims data for the prevalence of medical conditions and use of drugs likely to cause QT prolongation in patients with schizophrenia. Curr Ther Res Clin Exp (2003) 0.75
Approach to wide complex tachycardias in patients without structural heart disease. Heart (2006) 0.75
Incidence of Sustained Ventricular Tachycardia in Patients with Prolonged QTc After the Administration of Azithromycin: A Retrospective Study. Drugs Real World Outcomes (2016) 0.75
Prevention of Pazopanib-Induced Prolonged Cardiac Repolarization and Proarrhythmic Effects. Arq Bras Cardiol (2014) 0.75
QTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy. Eur J Clin Pharmacol (2002) 0.75
Drug-induced torsades de pointes in an underserved urban population. Methadone: is there therapeutic equipoise? J Interv Card Electrophysiol (2015) 0.75
Retracted Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet (1998) 36.93
Delineation of prognostic biomarkers in prostate cancer. Nature (2001) 12.25
Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS (2001) 8.89
Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS (2000) 8.86
Cardiopulmonary resuscitation skills of preregistration house officers. Br Med J (Clin Res Ed) (1985) 8.45
Heart rate variability: origins, methods, and interpretive caveats. Psychophysiology (1997) 7.81
Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation (2001) 7.47
Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature (1998) 7.26
Total excitation of the isolated human heart. Circulation (1970) 7.04
Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet (1993) 6.53
Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ (1995) 6.28
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 5.42
Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res (2003) 5.39
Cellular basis for the electrocardiographic J wave. Circulation (1996) 5.25
Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation (1999) 5.04
Sequence and analysis of chromosome 4 of the plant Arabidopsis thaliana. Nature (1999) 5.03
Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent. Circ Res (1999) 4.57
A prospective study of dietary glycemic load, carbohydrate intake, and risk of coronary heart disease in US women. Am J Clin Nutr (2000) 4.38
Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation (1998) 4.13
Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation (2000) 3.99
The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion. Cardiovasc Res (1988) 3.98
Cooperation, control, and concession in meerkat groups. Science (2001) 3.79
Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction. Lancet (1999) 3.38
Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice. Proc Natl Acad Sci U S A (1991) 3.19
Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J (1994) 3.13
Slow conduction in the infarcted human heart. 'Zigzag' course of activation. Circulation (1993) 3.13
DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage. J Mol Biol (1996) 3.08
Proposed diagnostic criteria for the Brugada syndrome. Eur Heart J (2002) 3.01
Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med (1999) 2.99
Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation (1997) 2.95
Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J (2001) 2.93
Reentry as a cause of ventricular tachycardia in patients with chronic ischemic heart disease: electrophysiologic and anatomic correlation. Circulation (1988) 2.86
Cardiac conduction defects associate with mutations in SCN5A. Nat Genet (1999) 2.73
Chlamydia pneumoniae and coronary heart disease. BMJ (1997) 2.73
Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci U S A (1992) 2.73
Colour Doppler flow mapping. BMJ (1990) 2.69
Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation (2001) 2.65
Phytoremediation of soil metals. Curr Opin Biotechnol (1997) 2.60
Ionic bases for electrophysiological distinctions among epicardial, midmyocardial, and endocardial myocytes from the free wall of the canine left ventricle. Circ Res (1993) 2.59
The Brugada syndrome: clinical, electrophysiologic and genetic aspects. J Am Coll Cardiol (1999) 2.56
Early repolarization syndrome: clinical characteristics and possible cellular and ionic mechanisms. J Electrocardiol (2000) 2.54
Identification and purification of two distinct complexes containing the five RAD51 paralogs. Genes Dev (2001) 2.54
Left atrial appendage: structure, function, and role in thromboembolism. Heart (1999) 2.52
Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart (1997) 2.50
Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation (2001) 2.50
Transient outward current prominent in canine ventricular epicardium but not endocardium. Circ Res (1988) 2.49
Characteristics and distribution of M cells in arterially perfused canine left ventricular wedge preparations. Circulation (1998) 2.48
Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. J Am Coll Cardiol (2000) 2.42
Cost implications of the British Pacing and Electrophysiology Group's recommendations for pacing. BMJ (1992) 2.42
Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogram. J Am Coll Cardiol (1991) 2.42
Post-infarction depression and incomplete recovery 6 months after acute myocardial infarction. Lancet (1994) 2.39
Transmural heterogeneity of ventricular repolarization under baseline and long QT conditions in the canine heart in vivo: torsades de pointes develops with halothane but not pentobarbital anesthesia. J Cardiovasc Electrophysiol (2000) 2.38
Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr (2001) 2.35
American College of Sports Medicine position stand. Exercise and type 2 diabetes. Med Sci Sports Exerc (2000) 2.32
Pathophysiology and prevention of atrial fibrillation. Circulation (2001) 2.31
The prognostic value of the QT interval and QT interval dispersion in all-cause and cardiac mortality and morbidity in a population of Danish citizens. Eur Heart J (1998) 2.28
Larger late sodium conductance in M cells contributes to electrical heterogeneity in canine ventricle. Am J Physiol Heart Circ Physiol (2001) 2.27
Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart (2002) 2.23
The QT interval. Prog Cardiovasc Dis (2001) 2.22
Short- and long-term reproducibility of QT, QTc, and QT dispersion measurement in healthy subjects. Pacing Clin Electrophysiol (1994) 2.21
Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome. Circulation (1997) 2.20
Sequence and analysis of chromosome 5 of the plant Arabidopsis thaliana. Nature (2000) 2.16
Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis. Laryngoscope (1997) 2.15
Sodium pentobarbital reduces transmural dispersion of repolarization and prevents torsades de Pointes in models of acquired and congenital long QT syndrome. J Cardiovasc Electrophysiol (1999) 2.14
Cellular basis for complex T waves and arrhythmic activity following combined I(Kr) and I(Ks) block. J Cardiovasc Electrophysiol (2001) 2.14
A subpopulation of cells with unique electrophysiological properties in the deep subepicardium of the canine ventricle. The M cell. Circ Res (1991) 2.14
Atrial arrhythmias. Lancet (1993) 2.13
Connexin-specific cell-to-cell transfer of short interfering RNA by gap junctions. J Physiol (2005) 2.12
Activation delay after premature stimulation in chronically diseased human myocardium relates to the architecture of interstitial fibrosis. Circulation (2001) 2.11
xIAP induces cell-cycle arrest and activates nuclear factor-kappaB : new survival pathways disabled by caspase-mediated cleavage during apoptosis of human endothelial cells. Circ Res (2001) 2.10
Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol (2000) 2.08
A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats. Neuropsychopharmacology (2008) 2.07
Colorectal carcinoma in Indian children. Indian Pediatr (2000) 2.07
Clinical evaluation of no-carrier-added meta-[123I]iodobenzylguanidine for myocardial scintigraphy. Eur J Nucl Med (2000) 2.06
Translation of the diabetes nutrition recommendations for health care institutions: technical review. J Am Diet Assoc (1997) 2.06
Ventricular tachycardia in the infarcted, Langendorff-perfused human heart: role of the arrangement of surviving cardiac fibers. J Am Coll Cardiol (1990) 2.05
The rhythm of the heart in active elderly subjects. Am Heart J (1980) 2.02
A molecular link between the sudden infant death syndrome and the long-QT syndrome. N Engl J Med (2000) 2.02
Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf (2001) 2.02
Complete denervation of the heart in a child with congenital long QT and deafness. Am J Cardiol (1988) 2.00
Polyethylenimine but not cationic lipids promotes transgene delivery to the nucleus in mammalian cells. J Biol Chem (1998) 1.98
A prognostic computer model to individually predict post-procedural complications in interventional cardiology: the INTERVENT Project. Eur Heart J (1999) 1.98
Cardiac arrhythmia suppression trial and flecainide. Lancet (1989) 1.98
Exciton condensation and charge fractionalization in a topological insulator film. Phys Rev Lett (2009) 1.98
Adjuvant xamoterol or metoprolol in patients with malignant ventricular arrhythmia resistant to amiodarone. Lancet (1989) 1.96
Independent origin of mono-rifampin-resistant Mycobacterium tuberculosis in patients with AIDS. Am J Respir Crit Care Med (1996) 1.93